Clinical trial · Interventional
The Effect of Complex Decongestıve Therapy on Oxıdatıve Stress and Antıoxıdants
The Effect of Complex Decongestıve Therapy on Oxıdatıve Stress and Antıoxıdants In Patıents Wıth Lymphedema After Breast Cancer Treatment
NCT06572098CI-TRIAL-00080993enrolling by invitationN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is aimed to determine the changes of complex decongestive therapy applications on oxidative stress parameters and antioxidants in patients with lymphedema after breast cancer treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| What Are the Effects of Lymphedema Treatment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Complex decongestive therapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- working group
- description
- Patients will receive ten sessions of complex decongestive therapy. Patients will be evaluated for oxidative stress and antioxidant levels in three stages: before treatment, immediately after treatment and one month after the end of treatment.
- interventionNames
- Other: Complex decongestive therapy
- type
- NO_INTERVENTION
- label
- control group
- description
- As an evaluation parameter, a healthy female control group will be formed at least as many as the number of patients with lymphedema included in the study.
Primary outcomes (1)
- measure
- PON1
- timeFrame
- will be assessed before treatment, immediately after treatment and one month after treatment.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Development of lymphedema after breast cancer treatment * Clinical stage of lymphedema Stage-2 or Stage-3 diagnosis Exclusion Criteria: * Receiving treatment for lymphedema in the last three months * Those diagnosed with severe heart failure and/or arrhythmia * Persistent infection in the affected extremities * Ongoing chemotherapy treatment * Diagnosed with liver disease
References
Publications (2)
- BACKGROUNDO'Toole J, Jammallo LS, Skolny MN, Miller CL, Elliott K, Specht MC, Taghian AG. Lymphedema following treatment for breast cancer: a new approach to an old problem. Crit Rev Oncol Hematol. 2013 Nov;88(2):437-46. doi: 10.1016/j.critrevonc.2013.05.001. Epub 2013 Jun 16. PMID 23777977
- BACKGROUNDCormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010 Nov 15;116(22):5138-49. doi: 10.1002/cncr.25458. PMID 20665892